Featured Paper of the Month – November 2023
Published in Translational Psychiatry by Jacqueline Keighron and Gianluigi Tanda, et al. of the NIDA IRP Medication Development Program.
Summary
Typical (cocaine-like) and atypical dopamine uptake inhibitors (DUIs) prefer distinct conformations of the dopamine transporter (DAT) to form ligand-transporter complexes, which may result in DAT interactions with other proteins and in markedly different effects on behavior, neurochemistry, and potential for addiction. Here we show that pretreatments with an inhibitor of CaMKIIα, a kinase that interacts with DAT and regulates synapsin phosphorylation and mobilization of reserve pools of DA vesicles, blunted the effects of cocaine on evoked DA release without affecting cocaine inhibition of DA reuptake. This effect is related to a specific DAT conformation stabilized by cocaine. In addition, atypical DUIs, which prefer a distinct DAT conformation, blunt cocaine’s neurochemical and behavioral effects, indicating a unique mechanism underlying their potential as medications for treating psychostimulant use disorder.
Publication Information
Interactions of calmodulin kinase II with the dopamine transporter facilitate cocaine-induced enhancement of evoked dopamine release Journal Article
In: Transl Psychiatry, vol. 13, no. 1, pp. 202, 2023, ISSN: 2158-3188.